Company intelligence / Profile preview

Kangyuan Botron Biotechnology

Beijing, Beijing, Chinazskybio.com ↗
Ownership
Private
Development stage
Other
01

Overview

The company is developing personalized dendritic cell therapeutic vaccines for cancer and possibly other indications; at least one program is in Phase 1 clinical trials, with others in earlier stages

Therapeutic areas
EndocrinologyNeurologyOncology
Modalities
Therapeutic vaccine
Industry
Biotech

Beyond the preview

Go deeper on Kangyuan Botron Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kangyuan Botron Biotechnology.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call